On this page
calcipotriene
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Calcipotriene | 50 ug/g | 198373 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Vitamin D Analog [EPC] | EPC | All 10 members |
| Vitamin D [CS] | CS | 5 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 205772-001 | CALCIPOTRIENE | CREAM | CALCIPOTRIENE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 7 | Labeling | Approved | April 17, 2026 | Standard |
| Original application | 1 | Approved | June 9, 2015 | Standard |
Review documents
- 0 · Original application · June 11, 2015
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251027). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin layer of Calcipotriene Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Calcipotriene Cream have been demonstrated in patients treated for eight weeks.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Calcipotriene Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene Cream should not be used on the face.
Warnings
openFDA Drug LabelingWARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of Calcipotriene Cream.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions associated with the use of calcipotriene cream have been identified post-approval: contact dermatitis, including allergic contact dermatitis. To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Calcipotriene Cream USP, 0.005% contains calcipotriene, USP, a synthetic vitamin D 3 derivative, for topical dermatological use. Chemically, calcipotriene, USP is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol, with the empirical formula C 27 H 40 O 3 , a molecular weight of 412.62 and the following structural formula: Calcipotriene, USP is a white or almost white crystalline powder. Calcipotriene Cream USP, 0.005% contains 50 mcg/g anhydrous calcipotriene, USP in a cream base of benzyl alcohol, cetostearyl alcohol, ceteth-20, disodium hydrogen phosphate dihydrate, glycerin, medium chain triglycerides, mineral oil, monosodium phosphate monohydrate, purified water and white petrolatum. Y:\Regulatory Affairs 2\ANDAs\Calcipotriene cream (205772)\_Misc\Northstar\structure.jpg
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of topical calcipotriene. If elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored. (See PRECAUTIONS .)
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Calcipotriene Cream, 0.005% is available in: 60 gram aluminum tubes (NDC 66993-877-61) 120 gram aluminum tubes (NDC 66993-877-78)
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CALCIPOTRIENE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | March 15, 2017 | LEO PHARMA INC | Incorrect/Undeclared excipients: inadvertent omission of a drug excipient from the the Authorized Generic label and also a warning regarding contact dermatitis from the brand product labeling not being incorporated into the Authorized Generic labeling. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 68462-501-65 | 68462-501 | Glenmark Pharmaceuticals Inc.,USA | 1 TUBE in 1 CARTON (68462-501-65) / 60 g in 1 TUBE | June 10, 2015 |
| 68462-501-66 | 68462-501 | Glenmark Pharmaceuticals Inc.,USA | 1 TUBE in 1 CARTON (68462-501-66) / 120 g in 1 TUBE | June 10, 2015 |
| 16714-763-01 | 16714-763 | Northstar Rx LLC | 1 TUBE in 1 CARTON (16714-763-01) / 60 g in 1 TUBE | May 1, 2018 |
| 16714-763-02 | 16714-763 | Northstar Rx LLC | 1 TUBE in 1 CARTON (16714-763-02) / 120 g in 1 TUBE | May 1, 2018 |
| 66993-877-61 | 66993-877 | Prasco Laboratories | 1 TUBE in 1 CARTON (66993-877-61) / 60 g in 1 TUBE | October 1, 1996 |
| 66993-877-78 | 66993-877 | Prasco Laboratories | 1 TUBE in 1 CARTON (66993-877-78) / 120 g in 1 TUBE | October 1, 1996 |
| 68462-501 | 68462-501 | Glenmark Pharmaceuticals Inc.,USA | — | June 10, 2015 |
| 16714-763 | 16714-763 | Northstar Rx LLC | — | June 1, 2015 |
| 66993-877 | 66993-877 | Prasco Laboratories | — | October 1, 1996 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.